Literature DB >> 9816295

Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues.

I Y Kim1, H J Ahn, D J Zelner, J W Shaw, S Lang, M Kato, M G Oefelein, K Miyazono, J A Nemeth, J M Kozlowski, C Lee.   

Abstract

Transforming growth factor beta1 (TGF-beta1) is a potential regulator of prostate cancer cell growth that signals through a heteromeric complex composed of type I and type II receptors. In the present study, an attempt was made to establish a correlation between expression of TGF-beta receptors and tumor grade in archival human prostate cancer tissues. To this end, immunohistochemical studies for TGF-beta receptors were carried out on 32 cases of human prostate cancer and 8 samples of benign human prostate. In both benign and malignant human prostate tissues, immunoreactivity for both type I and type II receptors was detected predominantly in epithelial cells. In addition, there was an inverse correlation between the loss of expression of TGF-beta1 type I and type II receptors and the tumor grade. Of the 32 prostate cancer cases screened, staining was completely absent in four samples for type II receptor (P < 0.05) and eight samples for type I receptor (P < 0.025). In contrast, all eight samples of benign prostate tissues investigated in this study showed strong staining for both type I and type II receptors. These results, taken together, indicate that human prostate cancer cells frequently have loss of expression of TGF-beta type I and/or type II receptors. Furthermore, these observations provide a potential mechanism for prostate cancer cells to escape the growth-inhibitory effect of TGF-beta.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9816295

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  26 in total

1.  Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death.

Authors:  Sanjib Chowdhury; Gillian M Howell; Carol A Teggart; Aparajita Chowdhury; Jonathan J Person; Dawn M Bowers; Michael G Brattain
Journal:  J Biol Chem       Date:  2011-07-08       Impact factor: 5.157

Review 2.  Gene targeting to the stroma of the prostate and bone.

Authors:  Roger S Jackson; Omar E Franco; Neil A Bhowmick
Journal:  Differentiation       Date:  2008-05-20       Impact factor: 3.880

3.  Evaluation of the prognostic value of TGF-β superfamily type I receptor and TGF-β type II receptor expression in nasopharyngeal carcinoma using high-throughput tissue microarrays.

Authors:  Wenling Zhang; Zhaoyang Zeng; Songqing Fan; Jieru Wang; Jianbo Yang; Yanhong Zhou; Xiayu Li; Donghai Huang; Fang Liang; Minghua Wu; Ke Tang; Li Cao; Xiaoling Li; Wei Xiong; Guiyuan Li
Journal:  J Mol Histol       Date:  2012-03-06       Impact factor: 2.611

4.  Acceleration of c-myc-induced hepatocarcinogenesis by Co-expression of transforming growth factor (TGF)-alpha in transgenic mice is associated with TGF-beta1 signaling disruption.

Authors:  E Santoni-Rugiu; M R Jensen; V M Factor; S S Thorgeirsson
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

5.  Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.

Authors:  Fancai Zeng; Guoxiong Xu; Tiejun Zhou; Chengwan Yang; Xinyan Wang; Chun Peng; Hong Zhou
Journal:  Med Oncol       Date:  2011-11-16       Impact factor: 3.064

6.  Overexpression of FOXG1 contributes to TGF-beta resistance through inhibition of p21WAF1/CIP1 expression in ovarian cancer.

Authors:  D W Chan; V W S Liu; R M Y To; P M Chiu; W Y W Lee; K M Yao; A N Y Cheung; H Y S Ngan
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

7.  PPARδ promotes oncogenic redirection of TGF-β1 signaling through the activation of the ABCA1-Cav1 pathway.

Authors:  Nam-Gu Her; Seong-In Jeong; Kyucheol Cho; Tae-Kyu Ha; Jikhyon Han; Kyung-Phil Ko; Soon-Ki Park; Jin-Hee Lee; Min-Goo Lee; Byung-Kyu Ryu; Sung-Gil Chi
Journal:  Cell Cycle       Date:  2013-04-17       Impact factor: 4.534

8.  Analysis of TGF-B and TGF-B-RII in Thyroid Neoplasms from the United States, Japan, and China.

Authors:  Yoshiaki Imamura; Long Jin; Joseph P. Grande; Chin-Yang Li; T-R. Zheng; Lori A. Erickson; Ricardo V. Lloyd
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

9.  Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.

Authors:  X Li; V Placencio; J M Iturregui; C Uwamariya; A-R Sharif-Afshar; T Koyama; S W Hayward; N A Bhowmick
Journal:  Oncogene       Date:  2008-08-25       Impact factor: 9.867

Review 10.  [Chemotherapy of hormone refractory prostate carcinoma].

Authors:  M P Wirth; J Nippgen
Journal:  Urologe A       Date:  2003-11       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.